Pipeline

Advancing innovative therapies from discovery to delivery, transforming unmet needs into real-world solutions.

Pipeline

Turning Breakthroughs Into Tomorrow’s Standard of Care

At VivaMed BioPharma, our pipeline reflects our commitment to advancing innovative therapies for critical and underserved medical needs. Each asset represents a step forward in addressing conditions where existing treatments fall short. From preclinical optimization to late-stage clinical trials, we are focused on delivering transformative solutions in areas such as oncology, neurology, rare diseases, and autoimmune and inflammatory disorders.

Our end-to-end approach ensures every therapy is developed with precision, efficiency, and the highest standards of care. Explore our pipeline to see how we’re shaping the future of medicine—one breakthrough at a time.

End-to-End Development Expertise

Patient-Centered Innovation

Collaborative Partnerships

Streamlined Regulatory Pathways

Funding to Drive Success

Compound
Mechanism of Action
Class
Indication
Status
VM1974
Norepinephrine Reuptake Inhibitor (NRI)
NCE
Centralized Pain (Osteoarthritis)
Phase II
VM0102
Nicotinic Acetylcholine (nACh) Partial Agonist
NCE
Nociceptive Pain (Postoperative)
Preclinical
VM0120
Nicotinic Acetylcholine (nACh) Partial Agonist
NCE
Neuropathic Pain
Preclinical
VM2124
Cannabinoid Type 2 (CB1) Neutral Antagonist
NCE
Neuropathic Pain (Chemo Induced)
Phase I
VM1710
Cannabinoid Type 2 (CB2) Agonist
NCE
Centralized Pain (Fibromyalgia)
Preclinical
VM8156
Cannabinoid type 2 (CB2) Allosteric Modulator
NCE
Neuropathic Pain
Preclinical
VM6128
N-methyl-D-aspartate (NMDA) Antagonist
505(b)(2)
Centralized Pain (Refractory to Tx)
Phase II
VM0120
Nicotinic Acetylcholine (nACh) Agonist
NCE
Tobacco Use Disorder
Preclinical
VM6527
Cannabinoid Type 1 (CB1) Neutral Antagonist
NCE
Opioid Use Disorder
Preclinical
VM5100
Cannabinoid Broad Spectrum Modulator
BDS
Nutritional Supp. (OTC)
Research
HC0007
Stilbenoid Broad Spectrum Modulator
BDS
Maj. Depressive Disorder
Research
PS0101
Serotnin (5-HT) Partial Agonist
BDS
Post Traumatic Stress
Preclinical
IB1899
NMDA, nACh Antagonist, KOR, 5-HT Agonist
BDS
Substance Use Disorder
Research
TP3A66
TAAR 1 Agonist / GluR5 Kainate Antagonist
505(b)(2)
Stimulant Use Disorder
Phase II
EN1273
NMDA Antagonist / Anti-Muscarinic
505(b)(2)
Opioid Use Disorder
Phase II

Questions? Feel Free to Contact Us!

9 + 12 =